ERBB2 and breast carcinoma: Loganzo et al. generated MDA-MB-361 and JIMT-1 HER2+ breast cancer cells lines resistant to TM-ADC (trastuzumab–maytansinoid ADC, structurally similar to T-DM1) by multiple cycles for 3–4 months of 3 days of approximately IC80 TM-ADC treatment, followed by 4–11 days of incubation of the cells in the drug-free medium [25].